Geraldina Dominguez, Ph.D. Program Director, AIDS Malignancy Program Office of HIV and AIDS Malignancy National Cancer Institute

1. Funding Opportunities Annoucements
in HIV-Associated Malignancies
Office of HIV and AIDS Malignancy
National Cancer Institute

2. Thousand
Cancer in Africa: A Significant Problem
Adapted from Sylla and Wild, Int J
Cancer. 2012 Jan 15;130(2):245-50.

3. RFA-CA-13-010
Sub-Saharan African Collaborative HIV and Cancer
Consortia (U54)
 Solicit research projects that are conducted jointly between U.S.
investigators and investigators in a partnering sub-Saharan
African country.
 Projects must address high-priority research questions in HIVassociated cancers of the partnering African country.
 Activities should be conducted in the partnering African country
and should demonstrate an equal and shared partnership.
 Applicants must identify a distinct research theme and focus
activities around that theme.
 Research projects should either address a variety of topics for a
single category of cancer or one topic for a related group of
cancers.
 No clinical trials will be allowed but clinical research will be
allowed.

4. RFA-CA-13-010
Sub-Saharan African Collaborative HIV and Cancer
Consortia (U54)
 The RFA was developed in collaboration with the Fogarty
International Center (FIC).
 RFA will be open to all qualified applicants, not just D43
Research Training recipients.
 The U54 grant mechanism will be used.
 Supports a full range of research (basic, translational and clinical)
 Allows multiple projects in a single application
 Allows for scientific and programmatic input from OHAM staff
 Each application must propose 2-4 research projects and
necessary cores (Mentoring/Career Development &
Administrative/Coordinating Cores are mandatory).
 Applicants can request up to $750,000 TOTAL cost per year for
5 years.
 NCI and FIC expect to fund 6-7 awards (~$4.4 million)

5. RFA-CA-13-010 Important Dates
 Letter of Intent Due Date
 December 17, 2013
 Application Due Date
 January 17, 2014
 Scientific Merit Review (NCI DEA)
 March-April, 2014
 Advisory Council Review
 May 2014 (NCAB meets June 22-24, 2014)
 Earliest Start Date
 August 2014

6. U.S.-South Africa Program for Collaborative
Biomedical Research
 NOT-AI-13-066 (Notice of Intent to Publish a Request for Applications
for the U.S.-South Africa Program for Collaborative Biomedical
Research)
 To enhance cooperative biomedical research between U.S. and
South Africa
 The NIH and the MRC have allocated funds to support joint activities
under this program.
 FOCUS of the joint program:
 HIV/AIDS biomedical and behavioral research
 Tuberculosis
 HIV-related malignancies
 This RFA will support basic, translational, clinical, preventive or
epidemiological research projects.
 Clinical trials of drugs, biologics or diagnostics will not be allowed.
 Collaborating U.S. and South African Investigators will submit one
application.
 Each application will have at least one PI from each country
 Separate research budgets for each component
 Applications will be reviewed by NIH; MRC will not conduct a
separate review

7. Administrative Supplements for HIV/AIDS
Implementation Science in PEPFAR Settings
 NOT-AI-13-061 (Notice of Intent to Publish an Announcement for
Availability of Funds for Administrative Supplements for HIV/AIDS
Implementation Science in PEPFAR Settings)
 By November/December 2013
 This opportunity will be limited to investigators with current NIH
grant funding for research and research training being conducted
at PEPFAR-funded sites.
 One year projects that inform the PEPFAR program.
 Supplement requests cannot exceed $500,000 TOTAL cost
 Implementation science projects that build in-country research
capacity are encouraged.
 PEPFAR program areas of interest include:
 General Implementation Science for Treatment Programs;
 Metrics and Diagnostics;
 Integration of Other Services;
 Focus on Key Affected Populations (KAP);
 Behavioral Research; and
 Training and Health Systems.

8. Recently Released Program Annoucements
 Research on Malignancies in the Context of
HIV/AIDS (R01)
 PA-13-377
 http://grants.nih.gov/grants/guide/pa-files/PA-13 December 7, 2013 is the earliest submission
date
 Research on Malignancies in the Context of
HIV/AIDS (R21)
 PA-13-378
 http://grants.nih.gov/grants/guide/pa-files/PA-13 December 7, 2013 is the earliest submission
date